+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Cancer Monoclonal Antibodies"

From
From
Metastatic Cancer Drugs Global Market Report 2024 - Product Thumbnail Image

Metastatic Cancer Drugs Global Market Report 2024

  • Report
  • February 2024
  • 175 Pages
  • Global
From
From
From
Global Cancer Immunotherapy Market 2023-2027 - Product Thumbnail Image

Global Cancer Immunotherapy Market 2023-2027

  • Report
  • August 2023
  • 168 Pages
  • Global
From
US Bispecific Antibodies Market & Clinical Pipeline Insight 2028 - Product Thumbnail Image

US Bispecific Antibodies Market & Clinical Pipeline Insight 2028

  • Drug Pipelines
  • August 2023
  • 580 Pages
  • United States
From
Global Cancer Immunotherapy Market Analysis & Forecast to 2025 - Product Thumbnail Image

Global Cancer Immunotherapy Market Analysis & Forecast to 2025

  • Report
  • November 2020
  • 450 Pages
  • Global
From
CAR-T Therapies Market (2nd Edition), 2019-2030 - Product Thumbnail Image

CAR-T Therapies Market (2nd Edition), 2019-2030

  • Report
  • August 2019
  • 580 Pages
  • Global
From
From
Loading Indicator

Cancer Monoclonal Antibodies (mAbs) are a type of oncology drug used to treat cancer. They are a type of biologic therapy, which means they are made from living cells. mAbs are designed to target specific proteins on cancer cells, which can help to slow or stop the growth of the cancer. They can be used alone or in combination with other treatments, such as chemotherapy or radiation therapy. mAbs can be used to treat a variety of cancers, including breast, lung, and colorectal cancer. The Cancer Monoclonal Antibodies market is a rapidly growing segment of the oncology drugs market. mAbs are becoming increasingly popular due to their ability to target specific proteins on cancer cells, which can help to reduce side effects and improve outcomes. Additionally, mAbs are often more cost-effective than other treatments, making them attractive to healthcare providers. Some of the major companies in the Cancer Monoclonal Antibodies market include Roche, Merck, Bristol-Myers Squibb, Amgen, and Novartis. Show Less Read more